SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-043701
Filing Date
2021-08-12
Accepted
2021-08-12 10:28:32
Documents
60
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q lrmr-10q_20210630.htm   iXBRL 10-Q 1833045
2 EX-31.1 lrmr-ex311_7.htm EX-31.1 14742
3 EX-31.2 lrmr-ex312_10.htm EX-31.2 14719
4 EX-32.1 lrmr-ex321_8.htm EX-32.1 14190
  Complete submission text file 0001564590-21-043701.txt   7249404

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA lrmr-20210630.xsd EX-101.SCH 51848
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE lrmr-20210630_cal.xml EX-101.CAL 50490
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE lrmr-20210630_def.xml EX-101.DEF 152673
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE lrmr-20210630_lab.xml EX-101.LAB 410170
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lrmr-20210630_pre.xml EX-101.PRE 300715
10 EXTRACTED XBRL INSTANCE DOCUMENT lrmr-10q_20210630_htm.xml XML 1365574
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36510 | Film No.: 211165902
SIC: 2834 Pharmaceutical Preparations